Board Review & Recertification Course

Whether you are preparing for board recertification or looking for a comprehensive clinical update, MSHO's Board Review Course provides an in-depth review of key topics in hematology and oncology. 

more information

Healthcare Bill Tracking

Track Healthcare Legislation Happening in Michigan!

Follow legislation that MSHO is actively monitoring that may impact you and your patients. 

more information

Previous Next

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

Upcoming Events view all events

 June 2026 
SMTWTFS
 123456
78
910111213
14151617181920
21222324252627
282930    
Sat
22
2026
August 22, 2026

Board Review & Re-Certification Course

Somerset Inn, Troy

view event details
Sat
26
2026
September 26 - 27, 2026

MSHO Annual Meeting

SAVE THE DATE!

Boyne Mountain Resort, Boyne Falls

view event details
Sat
26
2026
September 26, 2026

Update in Hematology and Oncology

SAVE THE DATE!

Boyne Mountain Resort, Boyne Falls

view event details

Latest News view all news

FDA approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
06/26/2026

FDA approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

FDA approves Gilead's Trodelvy® in combination with Merck's KEYTRUDA® or KEYTRUDA QLEX™ for treatment of Advanced Triple-Negative Breast Cancer in adults
06/26/2026

FDA approves Gilead's Trodelvy® in combination with Merck's KEYTRUDA® or KEYTRUDA QLEX™ for treatment of Advanced Triple-Negative Breast Cancer in adults

FDA approves AstraZeneca's Datroway TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
06/17/2026

FDA approves AstraZeneca's Datroway TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

FDA approves AstraZeneca's Truqap combination as targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
06/17/2026

FDA approves AstraZeneca's Truqap combination as targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Corporate Sponsors view all sponsors